{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:42Z","timestamp":1788984822581,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01878-9","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:30:02Z","timestamp":1785684602000},"page":"4651-4665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-945X","authenticated-orcid":false,"given":"Hideaki","family":"Kagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5978-9002","authenticated-orcid":false,"given":"Shuichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-8601","authenticated-orcid":false,"given":"Naoto","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0385-1129","authenticated-orcid":false,"given":"Kiyotaka","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"issue":"1","key":"1878_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13555-023-01064-1","volume":"14","author":"Y Tada","year":"2024","unstructured":"Tada Y, Soliman AM, Ishii K, et al. Real-World Discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. Dermatol Ther (Heidelb). 2024;14(1):99\u2013114. https:\/\/doi.org\/10.1007\/s13555-023-01064-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1878_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450. https:\/\/doi.org\/10.1136\/bmjopen-2014-006450.","journal-title":"BMJ Open"},{"key":"1878_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdin.2020.10.011","volume":"2","author":"H Goto","year":"2021","unstructured":"Goto H, Nakatani E, Yagi H, Moriki M, Sano Y, Miyachi Y. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:51\u201361. https:\/\/doi.org\/10.1016\/j.jdin.2020.10.011.","journal-title":"JAAD Int"},{"issue":"5","key":"1878_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/1346-8138.17695","volume":"52","author":"H Torii","year":"2025","unstructured":"Torii H, Morita A, Yamamoto C, et al. Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: post-marketing surveillance. J Dermatol. 2025;52(5):787\u2013801. https:\/\/doi.org\/10.1111\/1346-8138.17695.","journal-title":"J Dermatol"},{"issue":"11","key":"1878_CR5","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317. https:\/\/doi.org\/10.1111\/1346-8138.16543.","journal-title":"J Dermatol"},{"issue":"12","key":"1878_CR6","doi-asserted-by":"publisher","first-page":"16355","DOI":"10.1007\/s00210-025-04334-1","volume":"398","author":"AE Elsisi","year":"2025","unstructured":"Elsisi AE, Abu-Risha SE-S, Alkabbani MA, Ramadan LA, Sokar SS. Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(12):16355\u201384. https:\/\/doi.org\/10.1007\/s00210-025-04334-1.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1878_CR7","doi-asserted-by":"publisher","first-page":"2229465","DOI":"10.1080\/09546634.2023.2229465","volume":"34","author":"C Wang","year":"2023","unstructured":"Wang C, Torisu-Itakura H, Hanada T, et al. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study. J Dermatolog Treat. 2023;34(1):2229465. https:\/\/doi.org\/10.1080\/09546634.2023.2229465.","journal-title":"J Dermatolog Treat"},{"key":"1878_CR8","unstructured":"BIMZELX\u00ae (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis https:\/\/www.ucb.com\/sites\/default\/files\/2024-01\/bkz_approval_japan_december_2023-1.pdf (2023). Accessed 19 February 2026."},{"issue":"7","key":"1878_CR9","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","volume":"39","author":"C Leonardi","year":"2022","unstructured":"Leonardi C, Zhu B, Malatestinic WN, et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan((R)) databases. Adv Ther. 2022;39(7):3214\u201324. https:\/\/doi.org\/10.1007\/s12325-022-02155-9.","journal-title":"Adv Ther"},{"issue":"2","key":"1878_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","volume":"34","author":"B Lockshin","year":"2021","unstructured":"Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther. 2021;34(2):e14808. https:\/\/doi.org\/10.1111\/dth.14808.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1878_CR11","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s13555-024-01274-1","volume":"14","author":"C Miyazaki","year":"2024","unstructured":"Miyazaki C, Masuda J, Tsai PI, Saeki H. Factors affecting treatment persistence in Japanese patients with psoriasis prescribed biologics: a real-world study using an insurance claim database. Dermatol Ther (Heidelb). 2024;14(11):2999\u20133015. https:\/\/doi.org\/10.1007\/s13555-024-01274-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1878_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364.","journal-title":"JAMA Dermatol"},{"key":"1878_CR13","unstructured":"Medical Data Vision (2026). MDV EBM Insight. https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/ Accessed 19 February 2026."},{"issue":"10","key":"1878_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","volume":"157","author":"SP Pourali","year":"2021","unstructured":"Pourali SP, Nshuti L, Dusetzina SB. Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the medicare population. JAMA Dermatol. 2021;157(10):1239\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3616.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1878_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379. https:\/\/doi.org\/10.1007\/s40257-021-00598-4.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1878_CR16","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","volume":"33","author":"M Kojanova","year":"2022","unstructured":"Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33(6):2827\u201337. https:\/\/doi.org\/10.1080\/09546634.2022.2082354.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1878_CR17","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/rheumatology\/kead089","volume":"62","author":"AWR Van Kuijk","year":"2023","unstructured":"Van Kuijk AWR, Nurmohamed MT, Siebert S, et al. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatol (Oxf). 2023;62(10):3382\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/kead089.","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"1878_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2021","unstructured":"Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2021;181(3):450\u20138. https:\/\/doi.org\/10.1111\/bjd.17738.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1878_CR19","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jdv.15733","volume":"33","author":"LS van der Schoot","year":"2019","unstructured":"van der Schoot LS, van den Reek J, Groenewoud JMM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913\u201320. https:\/\/doi.org\/10.1111\/jdv.15733.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1878_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03257-7","volume":"26","author":"A Deodhar","year":"2024","unstructured":"Deodhar A, Blauvelt A, Lebwohl M, et al. Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(1):49. https:\/\/doi.org\/10.1186\/s13075-023-03257-7.","journal-title":"Arthritis Res Ther"},{"key":"1878_CR21","unstructured":"Summary of Product Characteristics-Ixekizumab;. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200602148236\/anx_148236_en.pdf Accessed 19 February 2026."},{"issue":"24","key":"1878_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247549","volume":"13","author":"A-I Butacu","year":"2024","unstructured":"Butacu A-I, Toma C, Negulet I-E, et al. Updates on psoriasis in special areas. J Clin Med. 2024;13(24):7549.","journal-title":"J Clin Med"},{"issue":"4","key":"1878_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352. https:\/\/doi.org\/10.1111\/bjd.16736.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1878_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01395-6","volume":"9","author":"R Wade","year":"2020","unstructured":"Wade R, Sharif-Hurst S, Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst Rev. 2020;9(1):132. https:\/\/doi.org\/10.1186\/s13643-020-01395-6.","journal-title":"Syst Rev"},{"issue":"2","key":"1878_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaad.2020.09.064","volume":"84","author":"S Muddasani","year":"2021","unstructured":"Muddasani S, Fleischer AB Jr, Feldman SR. Treatment practices for psoriasis and how they are changing. J Am Acad Dermatol. 2021;84(2):579\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.064.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1878_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392. https:\/\/doi.org\/10.1007\/s40257-020-00578-0.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01878-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:28Z","timestamp":1788981688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01878-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hideaki Kagitani, Shuichi Kimura, Naoto Tsujimoto, and Kiyotaka Mochizuki are employees of Eli Lilly Japan K.K. and minor shareholders of Eli Lilly and Company. Yayoi Tada received grants from Eisai, Maruho, Torii, AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jimro, Kyowa Kirin, LEO Pharma, Sun Pharma, Taiho, Tanabe-Mitsubishi, UCB, Meiji Seika Pharma, Kaken and AbbVie; and honoraria from Eisai, Maruho, Torii, AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jimro, Kyowa Kirin, LEO Pharma, Sun Pharma, Taiho, Tanabe-Mitsubishi, UCB, and AbbVie, Janssen Pharma, Novartis Pharma.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practices. Per the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, ethical review and informed consent were not required, as this was a noninterventional, retrospective study that used anonymized patient data. While conducting this study, we had permission to access the MDV database. The data were provided by MDV Co., Ltd. under a data use (license) agreement.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}